Super Crops or a Super Problem? The Battle over Bt Corn. Monsanto Company v. Bayer Bioscience N.V. by Stockhorst, Lee
Journal of Environmental and Sustainability Law 
Missouri Environmental Law and Policy Review 
Volume 15 
Issue 3 Summer 2008 
Article 3 
2008 
Super Crops or a Super Problem? The Battle over Bt Corn. 
Monsanto Company v. Bayer Bioscience N.V. 
Lee Stockhorst 
Follow this and additional works at: https://scholarship.law.missouri.edu/jesl 
 Part of the Environmental Law Commons 
Recommended Citation 
Lee Stockhorst, Super Crops or a Super Problem? The Battle over Bt Corn. Monsanto Company v. Bayer 
Bioscience N.V., 15 Mo. Envtl. L. & Pol'y Rev. 531 (2008) 
Available at: https://scholarship.law.missouri.edu/jesl/vol15/iss3/3 
This Note is brought to you for free and open access by the Law Journals at University of Missouri School of Law 
Scholarship Repository. It has been accepted for inclusion in Journal of Environmental and Sustainability Law by an 
authorized editor of University of Missouri School of Law Scholarship Repository. For more information, please 
contact bassettcw@missouri.edu. 
Super Crops or a Super Problem? The Battle over Bt Corn
Monsanto Company v. Bayer Bioscience N. V
I. INTRODUCTION
In Monsanto the Court works its way through a technical analysis
of patent law in order to determine which of two huge corporations has the
right to market a Bt corn produce. The case itself strictly adheres to
established precedent concerning the patentability of genetically modified
organisms and the impact that inequitable conduct has on the
enforceability of a patent. On the surface this case appears to be a bland
interpretation on a worn-out subject, but under the surface lies a more
complex issue. Every year more countries become reliant on genetically
modified crops for both production and consumption. The United States
alone plants approximately fifty-four million hectares of genetically
modified plants each year.3 As a result, there are billions of dollars to be
made for the company that holds the patent rights to lucrative genetically
modified organisms. What often gets lost in the corporate battle for patent
rights are the potential environmental impacts resulting from increased
exposure of indigenous plant and animal species to organisms that are
modified genetically.
II. FACTS
At its most basic, this case concerns patent infringement of
chimeric genes.4 Monsanto brought a declaratory judgment action against
' 514 F.3d 1229 (C.A.Fed. Mo. 2008).
2 Bacillus thuringiensis. Bacillus thuringiensis is a bacterium that parasitizes the
caterpillars of some harmful moths and butterflies. See, Bio-Medicine, http://www.bio-
medicine.org/biology-dictionary/Bacillus (last checked Aug. 11, 2008).
3 See Friends of the Earth International, Who benefits from the use of gm crops?: the rise
ofpesticide use (January 2008), available at
http://www.globalpolicy.org/socecon/trade/gmos/2008/0lwhobenefits.pdf (last checked
April 12, 2008).
4 An artificial gene constructed by juxtaposition of fragments of unrelated genes or other
DNA segments, which may themselves have been altered. Merriam-Webster Dictionary,
available at http://www.merriam-webster.com (last checked April 11, 2008).
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Bayer Bioscience ("Bayer") claiming unenforceability of four Bayer
patents, challenging the validity of the same four patents, and claiming the
transgenic corn products5 Monsanto marketed did not infringe upon the
four Bayer patents in question.6
This story began in 1986 when Plant Genetic Systems, N.V.7
obtained plants that expressed a truncated form of a specific Bt toxin. The
truncated Bt toxin was created through transformation of the plants using a
Bt toxin gene that encoded the first part of the toxin using Agrobacterium
tumefaciens ("Agrobacterium").
Monsanto sells genetically modified corn that expresses a Bt toxin
with the same amino acid sequencing Bayer claims to have invented in
1986.9 As a result Monsanto filed a declaratory judgment action seeking a
finding that Monsanto's genetically modified corn product did not infringe
upon Bayer patents '565, '372, '546, or '79910, and that those patents were
invalid and unenforceable." The district court granted summary judgment
in favor of Monsanto, holding all four patents unenforceable due to
inequitable conduct.12 The Court found certain patent claims invalid, and
decided that the Monsanto corn product did not infringe on the '565
patent.' 3
Bayer appealed to the Federal Circuit Court of Missouri. The Court
reversed as to construction of the term "Bt2 toxin" and vacated the
5 "Transgenic" defined as "being or used to produce an organism or cell of one species
into which one or more genes of another species have been incorporated." Merriam-
Webster Dictionary, available at http://www.merriam-webster.com (last checked April
11, 2008).
6 Friends of the Earth International, Who benefits from the use ofgm crops?: the rise of
pesticide use (January 2008), available at
http://www.globalpolicy.org/socecon/trade/gmos/2008/0lwhobenefits.pdf (last checked
April 12, 2008).
7 Naamloze Vennootschap, a Dutch public limited-liability company.
8 Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229, 1232 (C.A.Fed. Mo. 2008).
10 U.S. Patent Nos. 5,545,565 ("the '565 patent"); 5,767,372 ("the '372 patent");
6,107,546 ("the '546 patent"); and 5,254,799 ("the '799 patent"). See Monsanto, 514
F.3d at 1231.
" Monsanto, 514 F.3d at 1232.




unenforceability and invalidity judgments.14 The Court held that the
summary judgment based on inequitable conduct during prosecution of the
'799 patent "was improper because there were material facts in dispute,
and . . . the district court erred in giving collateral estoppel effect to an
earlier case between predecessors of the parties in this case and basing its
invalidity findings on this estoppel".15
On remand Bayer dismissed its previous claims that the Monsanto
corn product infringed on patent numbers '799, '372, and '546.16
Therefore, the case proceeded to trial on the issue involving the
infringement of the '565 patent. The jury found that Monsanto's
genetically modified corn product did not infringe on patent '565 and that
other claims relating to '565 were invalid for "obviousness and prior
invention by Monsanto."l 7 The district court conducted a four day trial
finding that inequitable conduct made all four patents in question
unenforceable.' 8
A. The Mariani Notes
During prosecution of the '565 patent, Bayer disclosed an abstract
created by Dr. Wayne Barnes, prepared in 1985, for a scientific
conference. At that conference, Barnes made a presentation about the uses
of the Bt toxin for insecticide and the applicable shortening process.
Bayer voluntarily disclosed this information during the prosecution, but
failed to disclose notes taken by Bayer employee, Dr. Celestina Mariani,
on the Barnes poster. Mariani's deposition explained that she made her
notes while standing in front of the poster.20 The notes even included
copies of schemes contained in the poster.21 The Court then discovered







9 Id. at 1235.20 id.
21 d
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Bt research group.22 In particular Dr. Wouter Meulemanns, an employee
in the intellectual property department at Bayer, admitted to seeing
Mariani's notes and talking to Mariani about the Barnes poster, but
Meulemanns testified that Mariani could not remember anything specific
about the presentation or poster.23 Dr. Meulemann's testimony was
unpersuasive and the court concluded that "Bayer had a duty of candor
and good faith to disclose the Mariani notes and intentionally withheld the
information from the United States Patent Office examiner in the
prosecution of the '565 patent with intention to deceive the PT0 24
examiner." 25 The finding of intent to deceive was fatal to Bayer's claims
of patent enforceability.
The Federal Circuit Court made three holdings in this case. First,
the Court affirmed the district court's conclusion that the Mariani notes
were material because the notes directly contradicted the arguments Bayer
made to the Patent and Trademark Office in an effort to support
patentability. 26 The Court reasoned that based on a "substantial likelihood
that a reasonable examiner would have considered the Barnes notes
important in deciding whether to allow the application to issue as a patent.
. . .)27 Second, the court concluded that Bayer's failure to disclose the
Mariani notes during prosecution for patent '565 was not sufficient to
prove inequitable conduct on its own, but that the district court did not err
in finding that Bayer had the requisite intent to deceive the PTO.28 Finally
the district court had jurisdiction to review inequitable conduct.29
22 id at 1236.
23 id
24 Patent & Trademark Office.
25 Monsanto, 514 F.3d at 1236.26 Id. at 1240. Understanding the patent process is an important element for analysis of
this case. The court glosses over the patent process requirements and moves directly into
"inequitable conduct" analysis, but no patent is enforceable unless it complies with the
requirements that the Patent & Trademark Office devises. See id.27 Monsanto, 514 F.3d at 1237.281 d. at 1239-42.




Three legal topics are essential to understanding the decision in
Monsanto. First, it is important to know some of the ins-and-outs of patent
law because the court did not explain the patent process in depth,
assuming the parties understood patent law, even though the process and
protocol for registering a patent is a pivotal issue in this case.30 Second,
the case deals almost entirely with making a determination of inequitable
conduct. Therefore, case precedent establishing the guidelines for making
a determination of "inequitable conduct" is critical both to the legal
scholar and the court. Finally, being presented with information about
previous influential patent law decisions involving genetically modified
organisms sheds light on some of the prevailing precedent and policy
concerns that went into this decision. Even though the court in Monsanto
never mentions the impact genetically modified organisms can have on the
environment, the continuing debate over the threat that such organisms
can pose to the environment requires extensive consideration because such
threats should be considered in any case involving genetically modified
organisms.
A. Registering a Patent
When the United States Patent and Trademark Office ("PTO") issues a
patent, a property right is granted to the inventor.31 Patents grant "the right
to exclude others from making, using, offering for sale, or selling" the
invention in the United States or "importing" the invention into the United
30 A critical issue in this case is the impact Bayer's failure to provide certain information
to the Patent and Trademark Officer has on the validity and enforceability of the patent.
Failure to disclose a material issue to the Patent and Trademark Officer during the
prosecution of a patent is a key element of "inequitable conduct." See Monsanto, 514
F.3d 1229 (C.A.Fed. Mo, 2008).
31 U.S. Patent & Trademark Office, General Information Concerning Patents (January
2005), http://www.uspto.gov/web/offices/pac/doc/general/index.html (last checked
February 29, 2008). Patents generally last 20 years from the date the application for
patent is filed in the United States. Id. In special cases the term of the patent begins on the
date that an earlier related patent application was filed. Id.
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States.32 The right is basically the right to exclude other people or
corporations from "making, using, offering for sale, selling or importing
the invention." 33 After a patent is issued the task of enforcement falls to
the patent holder. 34
Three types of patents are recognized: utility patents, design patents,
and plant patents.3 5  Utility patents involve machine, article of
manufacture, or composition of any matter, or any new and useful
improvement thereof."3 6 Design patents are granted to anyone inventin
"new, original, and ornamental design for an article of manufacture." 3
Finally, plant patents grant rights "to anyone who invents or discovers and




3 Id. While common sense may dictate that genetically modified organisms should
receive a plant patent such organisms are actually patentable under a utility patent. See
J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc., 534 U.S. 124 (2001).
36 U.S. Patent & Trademark Office, A Guide to Filing a Non-Provisional (Utility) Patent
Application (June, 2005), http://www.uspto.gov/web/offices/pac/utility/utility.htm (last
checked February 29, 2008).
3 U.S. Patent & Trademark Office, A Guide to Filing a Design Patent Application (June,
2005), http://www.uspto.gov/web/offices/pac/design/index.html (last checked February
29, 2008).
3 U.S. Patent & Trademark Office, General Information About 35 U.S.C 161 Plant
Patents (June 2005), http://www.uspto.gov/web/offices/pac/plant/index.html (last
checked February 29, 2008).
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Not every invention is patentable. 39 According to the PTO, "[i]f the
invention has been described in a printed publication anywhere in the
world, or if it was known or used by others in this country before the date
that the applicant made her invention, a patent cannot be obtained."4o A
patent is not guaranteed just because the invention seeking a patent has
differences from a nearly similar patented invention. The PTO demands
"the subject matter sought to be patented must be sufficiently different
from what has been used or described before that it may be said to be non-
obvious to a person having ordinary skill in the area of technology related
to the invention."41
Only an inventor can apply for a patent.42 If someone other than the
inventor applies for a patent, and the patent is obtained, the patent is
invalid.43 If a person falsely states that he is the inventor, he is subject to
criminal penalties. Innocent mistakes in "erroneously omitting an inventor
or in erroneously naming a person as an inventor" are correctable."
B. Inequitable Conduct
3 The power to enact patent laws is found in Article 1, section 8 of the United States
Constitution. The section says "Congress shall have power...to promote the progress of
science and useful arts, by securing for limited times to authors and inventors the
exclusive right to their respective writings and discoveries." U.S. CONsT., Art. I., § 8. In
1952 patent laws were revised and codified in Title 35 of the United States Code. See
U.S. Patent & Trademark Office, General Information Concerning Patents (January
2005), http://www.uspto.gov/web/offices/pac/doc/general/index.html (last checked
February 29, 2008). In November of 1999 the American Inventors Protection Act
("AIPA") was enacted to further revise patent laws. U.S. Patent & Trademark Office,
General Information Concerning Patents (January 2005),
http://www.uspto.gov/web/offices/pac/doc/generallindex.html (last checked February 29,
2008). If an applicant makes the request the amendments provide for the "continued
examination of an application for a fee. 35 U.S.C. § 132 (2002).
40 U.S. Patent & Trademark Office, General Information Concerning Patents (January
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In Monsanto, it was alleged that the Bayerpatents were invalid and
thus unenforceable due to inequitable conduct. The appellate court
agreed that patent '565 was unenforceable due to inequitable conduct;
therefore, the appellate court focused review on the district court's
inequitable conduct holdings.46 The established standard of review for
inequitable conduct determinations is to "review the district court's
findings on the threshold issues of materiality and intent for clear error." 47
To find a patent unenforceable for inequitable conduct a court must find
by clear and convincing evidence that "a patent applicant breached its duty
of candor and good faith to the PTO by failing to disclose material
information, or submitting false material information, with an intent to
deceive the PTO."48
Precedent has established that information is material for inequitable
conduct decisions if "a reasonable examiner would have considered such
[information] important in deciding whether to allow the patent
application.'A9 Rule 56 defines materiality as:
information that is not cumulative to information already of record or
being made of record in the application, and that (1) establishes, by
itself or in combination with other information, a prima facie case of
unpatentability of a claim; or (2).. .refutes, or is inconsistent with, a
position the applicant takes in: (i) Opposing an argument of
unpatentability relied on by the Office, or (ii) asserting an argument of
patentability.50
45 Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229, 1232-33 (C.A.Fed. Mo.
2008)..
46 Id. at 1233 (citing eSpeed, Inc. v. Brokertec USA L.L.C., 480 F.3d 1129, 1138-1139
(Fed. Cir. 2007)).
4 7 Id. (quoting Cargill, Inc. v. Cambra Foods, Ltd., 476 F.3d 1359, 1365 (Fed.Cir. 2007)).48 1d. at 1233-34 (citing Bruno Indep. Living Aids, Inc. v. Acorn Mobility Servs. Ltd.,
394 F.3d 1348, 1351 (Fed.Cir. 2005)); see also Kingsdown Med. Consultants, Ltd. v.
Hollister, Inc., 863 F.2d 867, 872 (Fed.Cir. 1988); see also Monsanto Co. v. Bayer
Bioscience N.V., 363 F.3d 1235, 1239 (C.A. Fed. Mo. 2004) (explaining that inequitable
conduct can be found when the "applicant omitted or misrepresented material facts with
the intention of misleading or deceiving the patent examiner").49 Monsanto, 514 F.3d at 1236 (quoting Digital Control, Inc. v. Charles Mach. Works,
437 F.3d 1309, 1314 (Fed.Cir. 2006)).
'0 37 C.F.R. § 1.56 (2000).
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A key element in a finding of inequitable conduct is the intent to
deceive.5 Absent a credible reason to explain withholding information,
"intent may be inferred where a patent applicant knew, or should have
known, that withheld information would be material to the PTO's
consideration of the patent application." 52 Withholding information in
good faith does not negate "an intent to manipulate the evidence when an
applicant knows or obviously should know that information would be
material to the examiner."53
Several factors contribute to ensuring the validity of a patent. First,
the patent must meet the specifications the PTO laid out defining
inventions eligible for patent. In the case of the genetically modified corn
at issue here, the inventors were required to meet the specifications of a
plant patent. Only after the inventors had established the patentability of
the corn was a patent issued. Once the patent is issued, the validity and
enforceability is challengeable on the basis of inequitable conduct. In
order to prove inequitable conduct a challenger must prove three elements.
First, that information was withheld from the PTO.54 Second, that the
information withheld from the PTO was material to the issuance of a
patent.5 5 Finally, the material information was withheld with the intent to
deceive the PTO.56 The court in Monsanto considered each of these factors
5' Monsanto, 514 F.3d at 1234 (citing Bruno Indep. Living Aids, Inc. v. Acorn Mobility
Servs. Ltd., 394 F.3d 1348, 1351 (Fed.Cir. 2005)); see also Kingsdown Med.
Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867, 872 (Fed.Cir. 1988); see also Monsanto
I, 363 F.3d at 1239 (explaining that inequitable conduct can be found when the "applicant
omitted or misrepresented material facts with the intention of misleading or deceiving the
patent examiner").Monsanto, 514 F.3d at 1241 (citing Bruno Indep. Living Aids, 394 F.3d at 1354
(holding that an "inference of deceptive intent may fairly be drawn in the absence of a
credible explanation for the non-disclosure.")).
s3 Cargill, Inc. v. Canbra Foods, Ltd., 476 F.3d 1359, 1368 (Fed.Cir. 2007).
54 U.S. Patent & Trademark Office, General Information About 35 US. C. 161 Plant
Patents, http://www.uspto.gov/web/offices/pac/plant/index.html#1 (last checked
February 29, 2008).
ss 37 C.F.R. § 1.56 (2000).
56 Monsanto, 514 F.3d at 1233 (citing Bruno Indep. Living Aids, Inc. v. Acorn Mobility
Servs. Ltd., 394 F.3d 1348, 1351 (Fed.Cir. 2005); see also Kingsdown Med. Consultants,
Ltd. v. Hollister, Inc., 863 F.2d 867, 872 (Fed.Cir. 1988); see also Monsanto 1, 363 F.3d
at 1239 (explaining that inequitable conduct can be found when the "applicant omitted or
539
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in making the determination that the Bayer patents were unenforceable for
inequitable conduct.
C. Notable GMO Patent Cases
Several cases have developed strong support for the patentability
of genetically modified organisms. Diamond v. Chakrabarty5 7 is one such
case. At over twenty years old, the United States Supreme Court's
decision that living organisms were not outside the scope of patentability 8
still stands and continues to influence all cases involving genetically
modified organism patents. 59 In 1972, Charkrabarty filed a patent
application for the invention of a bacterium. 60 The engineered bacterium
was capable of breaking down multiple components of crude oil.61 In its
analysis the Court determined that 35 U.S.C. § 101, which outlined the
realm of patentability, was very broad.62 The Court concluded that the
engineered bacterium was patentable because the claim "[was] not
... unknown natural phenomenon, but to a non-naturally occurring
manufacture or composition of matter - a product of human ingenuity
"having a distinctive name, character [and] use."63 This holding opened
the door to the future of genetically modified organisms by providing
protection to companies with an interest in creating such organisms.
J.E.M Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc. is
another notable case. Pioneer brought an action alleging infringement of
patents involving plants and seed for varieties of hybrid and inbred corn.
J.E.M.65 bought patented hybrid seeds from Pioneer in bags that bore a
misrepresented material facts with the intention of misleading or deceiving the patent
examiner").
s7 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
58 id.
5 The court in Monsanto never discussed the issue of whether the Bt Corn gene, or the
resulting product, were patentable because case precedent has clearly established the
patentability of such products.
Diamond, 447 U.S. at 304-05.
61 id
62 Diamond, 447 U.S. at 309-10.63id
J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc, 534 U.S. 124 (2001).65J.E.M. was doing business as "Farm Advantage, Inc." Id. at 128.
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license agreement restricting use of the seed for propagation.6 J.E.M.
subsequently resold these bags in violation of the licensing agreement.
The case is important for two reasons. First, the court agreed with the
reasoning in Chakrabarty that 35 U.S.C. § 10167 has broad scope and
applicability. Second, with the broad scope in mind, the Court held that
utility patents can be issued for plants. 69 Specifically, that newly
developed plant breeds are included in the terms of § 10 1.70 After finding
that plants could receive a utility patent, the Court went on to find that
J.E.M. infringed on the Pioneer-held patent by re-selling the seed
product.7 The real importance of this decision is that, in validating the
patentability of newly developed plant breeds, the Court indirectly
encouraged the growth and development of researching and creating
genetically modified organisms.
IV. INSTANT DECISION
The Federal Circuit Court focused on two specific areas of interest:
the materiality of the Mariani notes and the district court credibility
finding.
A. Materiality ofMariani Notes
Three guidelines dominated the Court's decision on the materiality
of the Mariani notes. First, information is material in an inequitable
conduct determination "if a reasonable examiner would have considered
6 Id at 128. The label license read: "License is granted solely to produce grain and/or
forage. Id. [The license] does not extend to the use of seed from such crop or the progeny
thereof for propagation or seed multiplication. Id. The license also strictly prohibited the
"use of such seed or the progeny thereof for propagation or seed multiplication or for
production or development of a hybrid or different variety of seed." Id.
67 § 101 reads: "Whoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement thereof, may
obtain a patent therefore, subject to the conditions and requirements of this title." 35
U.S.C. § 101 (2000).6 jE.M Ag Supply, Inc., 534 U.S. at 131.
' Id. at 127.70 Id. at 145.
7n Id. at 124 (2001).
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such [information] important in deciding whether to allow the patent
application."72 Second, the court looked to the definition of material
information as provided in PTO Rule 56. Finally, the Court determined
that "a misstatement or omission that is material under the Rule 56
standard "is considered material for the purposes of the inequitable
conduct inquiry." 74
Bayer maintained that the district court's findings, that the Mariani
notes were material, were clearly erroneous because they were based on
allegations that Barnes used identical species of Bt toxin as Bayer used.
Bayer claimed that without this "erroneous finding of fact, there can be no
materiality."76
The court disagreed. While conceding that Bayer was correct in
that nothing on the record supported a finding that the Bt toxin highlighted
in the Bames abstract was identical to the Bt toxin covered in the '565
patent, the court determined that the district court did not have to find
Barnes used an identical Bt toxin. The Court posited six reasons in support
of this conclusion.77
First, when the Examiner first rejected the '565 patent, Bayer was
not limiting the patent claim to one species of Bt toxin, but was making
claims to a specific chimeric gene encoding.78 Therefore, any chimeric
gene that Barnes created within this particular genus directly implicated
Bayer's claims. 79 Second, neither the Examiner's rejections, nor any of
Bayer's arguments to overcome those rejections, relied on the exact Bt
toxin Barnes used.80 The critical issue was whether the Barnes Abstract
made the Bayer invention obvious absent unexpected results. Third, Bayer
ignored the district court's materiality finding that the Mariani notes
72 Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229, 1237 (C.A.Fed. Mo. 2008)
(citing Digital Control, Inc. v. Charles Mach. Works, 437 F.3d 1309, 1363 (Fed.Cir.
2006)).











showed the Barnes chimeric gene displayed toxicity when applied to
plants.8' Fifth, the district court clearly based its materiality on finding all
the factual findings through the opinion, including Mariani's very specific
testimony about the information included in the Barnes Abstract. 82 Finally
the court focused on the discrepancies between the interpretation of the
Barnes abstract posited by Bayer and the information that was actually
contained in the Mariani notes. 83 The court concluded that the Mariani
notes met the standard for materiality because they "clearly and
convincingly refute . . ., or [were] inconsistent with a position the
applicant took in opposing the Examiner's argument of unaptentability." 84
B. Determining Inequitable Conduct
After accepting the district courts materiality finding, the Federal
district court had only to apply the facts of the case to relevant case law
regarding inequitable conduct. In the Court's opinion Bayers' failure to
disclose the Mariani notes to the PTO was not enough to prove inequitable
conduct. Instead "clear and convincing evidence" must also establish an
intent to deceive the PTO.85 To prove intent, "the involved conduct,
viewed in light of all the evidence, including evidence of good faith, must
indicate sufficient culpability to require a finding of intent to deceive." 86
According to the Court, precedent established that "absent a credible
reason for withholding the information intent may be inferred where a
patent applicant knew, or should have known, that withheld information
would be material to the PTO's consideration of the patent application." 87
The Court determined that the district court did not err in finding
that the attempts made by Bayer to establish good faith were not
persuasive and in concluding that Dr. Meulmanns intentionally withheld
81 Id This information could indicate that Bayer utilized ideas in the Barnes abstract to
create its own Bt toxin. That would make the invention "similar" to the Barnes idea and,
thus, the Bayer Bt toxin gene might lack patentability.
82 id
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the Mariani notes in an attempt to deceive the PTO." Affirmation of the
district court's decision was further supported by the fact that explanations
that Bayer provided concerning failure to divulge the Mariani notes were
unconvincing in light of Mariani's thorough testimony. 89
V. COMMENT
A decade or so ago you could not turn on the television or read the
paper without seeing something about genetically modified organisms. As
consumer goods produced from genetically modified organisms began to
enter the marketplace, concern began to rise about the health and safety of
both consuming and producing such organisms.
A. Environmental Impact of G.M 0. 's
One of the main areas of concern surrounding the development,
utilization, and consumption of genetically modified organisms involved
the potential impact of such organisms on the environment.
Several negatives result from genetically modified organisms. One
concern is a reported increase in the overall use of pesticides, especially in
the United States, which is accompanied by increasing development of
super weeds that are resistant to herbicides. 90  One particular study
indicated that between 1996 and 2004, the United States saw a use of 122
million more pounds of pesticides than would have been applied if GM
crops had not been introduced.9' The use of so much pesticide has led to
increasing occurrences of herbicide resistant weeds. In an effort to contain
the resistant weeds, instances of mechanical tillage of increased
92contributing to soil erosion and global warming gas emissions.
88 Id.89 id.
9o See Friends of the Earth International, Who benefits from the use ofgm crops?: the rise







Another environmental concern arises from the basic idea of how
some G.M.O.'s, particularly Bt products, work on a basic level. If
ingested, Bt toxin will cause mortality in insects. 93 The toxins dissolve in
the gut of the insect and then punch a hole in the lining of the insect's gut
cells. 94 The Bt will then spill out of the gut into the insect resulting in
death of the insect within a few days.95 While Bt products are created to
target specific crop-destroying insects, there is nothing to say that other,
non-target insects, will not ingest the Bt toxin.96 This process could
threaten the survival of hundreds of insect species, not to mention the
potential unbalance in the ecosystem that could result from an insect
species being eradicated in a particular area.
However, not everything about genetically modified organisms is
negative. Despite the possible negative impacts on the environment, the
increased use of such organisms can have positive results. Today there are
more than 840 million people in the world who are malnourished. 7 More
than 153 million of those people are children under the age of five.98 Many
supporters of genetically modified organisms believe that G.M.O.'s that
are engineered for drought resistance, pest resistance, and to possess
particular vitamins are the answer to the world hunger problem.99
9 University of California, Bacillus thuringiensis, How does bt work?, available at
http://www.bt.ucsd.edu/how-bt-work.html (last checked April 12, 2008).
94 id.
95 Id
96 Several years ago there was controversy concerning the impact that Bt toxins were
having on Monarch Butterfly populations. A two-year study eventually indicated that the
impact on the butterflies was negligible. See Mark K. Sears et al., Impact ofBt corn
pollen on monarch butterfly populations: A risk assessment,
http://www.pnas.org/cgi/content/abstract/98/21/11937 (last checked April 12, 2008).
9 See CARE, Facts About Hunger, http://www.care.org/campaigns/world-
hunger/facts.asp (last checked April 12, 2008).
98 Id.
9 Golden Rice is one genetically modified food product that has been highly touted as an
end to world hunger. This transgenic rice contains beta-carotene and could help end
vitamin A deficiency around the world. See, Craig Holdrege & Steve Talbot, Golden
Genes and World Hunger: Let them Eat Transgenic Rice?,
http://online.sfsu.edul-rone/GEessays/goldengenes.htm (last checked April 12, 2008).
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B. The Question of Materiality & the Intent to Deceive
The court reviewed Bayer's actions, in obtaining the patents in
question, for inequitable conduct.' 00 Bayer neglected to inform the PTO
that Dr. Celestina Mariani had viewed the Barnes poster and provided
extensive notes on the contents of the poster to fellow Bayer scientists that
were ultimately responsible for creating the "Bt2" technology at issue in
these particular patents.' 0' The Federal Circuit Court of Missouri
determined that this was an omission of a material fact.102 The Court
established the intent to deceive the PTO required to find a patent
unenforceable for inequitable conduct because there was no credible
explanation for Bayer's failure to disclose this information. 0 3
Based on the facts of the case as applied to the rules for
determining inequitable conduct, it is difficult to attack the Federal
District Court's decision. There is no new shocking outcome or surprising
rewriting of patent law here. The formula for declaring unenforceability
for inequitable conduct has long been established by case law. 0 4
However, the court incorrectly interpreted key facts resulting in an
erroneous decision in favor of Monsanto.
The court wrongfully decided that the Mariani notes were material
and a basis for a finding of inequitable conduct. Case precedent has
established that information is material for inequitable conduct decisions if
"a reasonable examiner would have considered such [information]
important in deciding whether to allow the patent application."' 0 First, the
court incorrectly concluded that the Mariani notes included coding for the
Bt toxin that was identical to the Bt toxin coding sequence presented in the
10 Monsanto v. Bayer Bioscience N.V., 514 F.3d 1229 (C.A.Fed. Mo. 2008).
101 Id
102 id.
103 Monsanto, 514 F.3d at 1241 (citing Bruno Indep. Living Aids, 394 F.3d at 1354
(holding that an "inference of deceptive intent may fairly be drawn in the absence of a
credible explanation for the non-disclosure.")).
'0See Bruno Indep. Living Aids, Inc. v. Acorn Mobility Servs. Ltd., 394 F.3d 1348,
1351 (Fed.Cir. 2005); see also Kingsdown Med. Consultants, Ltd. v. Hollister, Inc., 863
F.2d 867, 872 (Fed.Cir. 1988); see also Digital Control, Inc. v. Charles Mach. Works,
437 F.3d 1309, 1314 (Fed.Cir. 2006).
o Monsanto, 514 F.3d at 1237 (quoting Digital Control, Inc. v. Charles Mach. Works,
437 F.3d 1309, 1314 (Fed.Cir. 2006)).
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Barnes abstract. While the Mariani notes contained code for the same
toxic protein that Bayer wanted to claim, it was not the same code as was
contained in the Barnes abstract. Monsanto never produced evidence or
testimony indicating that the toxin sequence code in the Mariani notes was
identical to the code in the Barnes abstract, but the court operates under
the assumption that the coding was "similar" enough to warrant the
disclosure of the notes to the PTO.106
Second, if the Court was correct in its finding that the Mariani
notes were material because the notes mentioned the coding for the toxin,
the notes are still immaterial because they became cumulative and
cumulative references are not considered material. 0 7 The earlier court
decision in Monsanto, 08 as well as the brief submitted to the court,
establish that the Patent and Trademark Officer had the Barnes abstract
and other supplemental material that contained information on coding for
the toxin.10 9 It is also indicated that at one point the Patent Officer argued
the unenforceability of the '565 patent based on the information in the
Barnes abstract and other supplemental information. Therefore, release of
the Mariani notes provided nothing new for the Patent and Trademark
Office to consider. The notes simply supplemented the information that
the Office already had before it which renders the notes cumulative. As
cumulative information, the notes can neither be deemed material nor
serve as the basis for a finding of inequitable conduct.
Third, without materiality, the inequitable conduct count fails and
the conjectures of Dr. Meulman's intent should not have been considered.
But even if the notes were actually material, the requisite intent was not
present. The intent to deceive "may be inferred where a patent applicant
knew, or should have known, that withheld information would be material
to the PTO's consideration of the patent application," without a credible
106 See Monsanto v. Bayer Bioscience, 514 F.3d 1229 (C.A.Fed. Mo. 2008).
107 Digital Control, Inc. v. The Charles Machine Works, 437 F.3d 1209, 1319 (Fed.Cir.
2006) (stating that "a withheld otherwise material prior art reference is not material for
the purposes of inequitable conduct if it is merely cumulative to that information
considered by the examiner.").
108 Monsanto v. Bayer Bioscience N.V., 514 F.3d 1229, (C.A. Fed. Mo. 1008).
0 Monsanto Co. v. Bayer Bioscience N.V., 363 F.3d 1235, 1239 (C.A. Fed. Mo. 2004);
see also Reply Brief of Defendant-Appellant Bayer Bioscience N.V., Monsanto v. Bayer
Bioscience N.V., 514 F.3d 1229, (C.A. Fed. Mo. 1008) (No. 2007-1109).
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reason explaining the withholding of information. 0 Nothing in the record
proves that Dr. Meulemanns had any knowledge of the contents of the
Mariani notes. Dr. Meulemanns testified that Mariani told him she could
remember nothing about the abstract and that there was nothing important
in the notes on the Barnes abstract."' There is no reason for the court to
doubt Dr. Meulemanns intent, especially in light of the fact that Mariani
never told him any important information was contained in the notes.11
C. Missouri Case Law in the Wake of Monsanto
The Monsanto decision does not appear to have affected
Missouri's approach to determining inequitable conduct. The court
followed clearly established precedent in making its determination that the
patents in question were unenforceable due to inequitable conduct. The
fact that the Court came to the incorrect conclusion was not due to
incorrect application of established law, but instead came from an
ineffective interpretation of the facts of the case. The process for
determining materiality and the requisite intent is subjective and gives the
court broad discretion in interpreting the facts of a given case and coming
to a decision on inequitable conduct. Therefore, it is arguable that the
court did not come to the wrong conclusion in Monsanto per se. It came to
the correct conclusion for the facts as the court chose to view them.
However, since the court viewed the facts incorrectly the conclusion of
inequitable conduct was tainted and invalid.
D. The United States Response to G.MO.'s
Countries around the world have adopted various approaches to
handling the production, consumption and sale of genetically altered
products. The United States adopted the Coordinated Framework for
Regulation of Biotechnology ("Framework") in an attempt to guarantee
110 (110) Monsanto, 514 F.3d at 1241 (citing Bruno Indep. Living Aids, 394 F.3d at 1354
(holding that an "inference of deceptive intent may fairly be drawn in the absence of a
credible explanation for the non-disclosure")).
"' Monsanto, 514 F.3d at 1236.
112 See Monsanto v. Bayer Bioscience, 514 F.3d 1229 (C.A.Fed. Mo. 2008).
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the safety of G.M.O.'s." 3 The Framework "instituted a "comprehensive
federal regulatory policy for.. .biotechnology research and products."l 4 It
established that the laws and regulations already in existence at the time
were sufficient to evaluate biotechnology products." 5  Under the
Framework the Food and Drug Administration ("FDA"), Environmental
Protection Agency ("EPA"), and the United States Department of
Agriculture ("USDA") monitored G.M.O.'s.1 6 The FDA is generally
responsible for food safety involving transgenic crop and animal food
products while the EPA monitors any health and environmental effects
that arise from "pest-protected plants," such as the Bt corn being fought
over in this patent case.' 17 The USDA focuses regulation on the effect of
G.M.O.'s, particularly genetically modified plants, on the other plants and
animals in an agricultural setting.1
In response to concerns about environmental safety, the
Environmental Protection Agency ("EPA") released information
indicating that Bt products are safe for use in the environment and with
mammals.119 The EPA has not found any human health hazards and has
gone so far as to exempt Bt from food residue tolerances, groundwater
restrictions, endangered species labeling, and special review
requirements.120 In fact, according to the EPA in the 50-year history of Bt-
" Gregory N. Mandel, Toward Rational Regulation of Genetically Modified Foods, 4
Santa Clara J. Int'l L. 21 (2006). The Framework was developed by the White House
Office of Science and Technology Policy in 1986. Id. at 21.
114 Id. (citing Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,
302 (June 26, 1986).
115 Mandel, supra note 113, at 21. The decision to regulate biotechnology products under
the controlling regulatory scheme in 1986 was largely influenced by the popularly held
belief that biotechnology was not risky in itself, so only the products resulting from
biotechnology required monitoring. Id.
'
1 Id.at21.
118 Id. Agency regulation generally occurs through application of statutes such as the
Federal Food, Drug, and Cosmetics Act (FFDCA), the Federal Insecticide, Fungicide,
and Rodenticide Act (FIFRA), and the Animal and Plant Health Inspection Service
(APHIS). See id.; see also Doug Farquhar, State Authority to Regulate Biotechnology
Under the Federal Coordinated Framework, 12 DRAKE J. AGRIC. L. 439 (2007).
119 See Bacillus Thuringiensis, Animal Safety, http://www.bt.ucsd.edu/bt-safety.html (last
checked April 12, 2008).
120 id
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based products, only two incidents of human allergic reaction have been
reported.121 The EPA also requires farmers planting transgenic crops,
such as the Bt corn involved in this case, to follow resistance management
requirements to help reduce the build-up of insect and pest resistance to
synthetic pesticides.' 22 However, the EPA admits that Bt can cause
adverse allergic reactions in some mammals such as rabbits.123
Some individual States within the United States have taken action
beyond the Federal Coordinated Framework, though many States "feel
that the primary responsibility for health and safety of biotechnology
should remain with the federal government." 24  The States that have
decided to attack the G.M.O. problem have generally done one of two
things. The State either provides funds or tax credits to support the
development of biotechnolopy development or the State bans G.M.O.'s
and their products outright.12
The State of North Dakota provides an interesting example of a
State that chose to fund biotechnology and support G.M.O.'s and then
considered banning certain genetically modified plants outright. In 2001
North Dakota proposed a ban on genetically modified wheat within the
state. The proposition was due largely to the fact that Japan, the main
purchaser of North Dakota wheat, had a ban on genetically modified
foods.126
The conundrum faced by North Dakota legislatures highlights a
second arena where the concerns of G.M.O.'s play out. Many G.M.O.'s,
and their products, are approved for consumption in European Union
member countries, but very few genetically modified crops have been
approved for cultivation.127 Starting in the early 1990s the EU developed
121 Id. In one instance the person was found to be suffering from a previous disease that
exacerbated the reaction and in the second case the individual had a history of life
threatening food allergies. Id
122 id
123 Id. The reaction was reported to be a mild irritation of the area around the eyes. Id.124 Farquhar, supra note 118, at 458. The reason for this sentiment is likely due to the fact
that many States do not have the resources or the availability to experts to replicate
federal studies. Id.
1251 d. at 459-60.
126 Id. at 460-61.
127 Margaret Rosso Grossman, The Coexistence of GM and Other Crops in the European
Union, 16 KAN. J.L. & PUB. POL'Y 324 (2007).
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a process requiring case-by-case authorization of G.M.O.'s, which
included components for traceability and labeling of GMO products.128
Many EU countries now practice "coexistence" which "focuses on
practices used to minimize adventitious presences."' 29
E. Missouri Response to GMO's
Missouri is a heavily focused agricultural state. There are over
100,000 farms in Missouri averaging 287 acres, comprising over 30
million acres of the state's land mass.130 Many of those farms produce
corn, soybeans, wheat and other agricultural products. With the growing
preference for genetically modified crops, the environmental concerns
surrounding G.M.O.'s undeniably affects Missouri's environment.131
In the last two years, bills have been introduced to both the
Missouri Senate and House of Representatives concerning pre-emption of
Missouri laws involving geneticall modified crops and products.132 Most
of the bills have failed to pass.13 However, in August 2007 Missouri
Governor Matt Blunt signed the Missouri Rice Certification Act into
law.134 The Act regulates the production, transportation and handling of
" Id. at 333.
Id. at 329-30. "Adventitious presence" is the "unavoidable variability in seed, grain,
and food" that occurs naturally over a long period of time in order to give a plant an
advantage for survival. Id. at 328-29.
130 See United States Department of Agriculture, Missouri State Agriculture Overview-
2006, available at
http://www.nass.usda.gov/StatisticsbyState/AgOverview/AgOverviewMO.pdf (last
checked April 12, 2008).
131 The United States is one of the biggest producers of genetically modified crops in the
world, producing over 50% of genetically modified crops alone. See, Friends of the Earth
International, Who benefits from the use ofgm crops?: the rise ofpesticide use, at 5-6
(January 2008), available at
http://www.globalpolicy.org/socecon/trade/gmos/2008/0lwhobenefits.pdf (last checked
April 12, 2008).
See Environmental Commons, 2007 Food Democracy Legislation Tracker,
http://environmentalcommons.org/tracker2007.html (last checked April 12, 2008).
133 d.
134 See Governor's Office, Blunt Discusses Agricultural Innovation and Technology at
Delta Center Field Day (August 2007), http://govemor.mo.gov/pressAug2007.htm
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specific rice varieties.135 The Act was proposed after it was discovered in
2006 that U.S. rice crops were contaminated by a strain produced by
Bayer CropScience. As a result, the U.S. lost the European Union rice
market.136 Though no statutory regulations exist in Missouri that apply
specifically to genetically modified organisms, the common law tort of
public nuisance is still available to farmers whose crops are altered by
cross-pollinating drift.137 The enactment of the Missouri Rice Protection
Act illustrates the concern that genetically modified organisms will have a
negative impact on native and non-native plant species.
It is clear that at this time, while Missouri acknowledges the
potential negative impacts of G.M.O.'s, that the state legislature still
believes that the benefits outweigh the costs. However, as more states sign
preemption statutes into law, impose greater restrictions on growing and
marketing genetically modified organisms, and enact liability statutes for
farmers who's crops cross-pollinate with non-genetically modified crops,
Missouri is likely to begin enacting more legislation that acknowledges the
potential threat such crops pose to Missouri's natural environment.
VI. CONCLUSION
Monsanto is not a groundbreaking decision that alters decades of
well-established case law. It is not the result of a highly publicized
corporate struggle over the cure for cancer. It does not possess a "sexy"
fact pattern that keeps the reader glued to the material. It is not a lot of
things, but the Monsanto decision is one thing - it is a reminder that
genetically modified organisms are still an important legal, political,
(follow "Blunt Discusses Agricultural Innovation and Technology at Delta Center Field
Day" hyperlink) (last checked April 12, 2008).
135 Rob Mayer, Missouri Senate, Missouri Rice Certification Act Protects Farmers from
GMOs (Feb. 19, 2007), available at
http://www.senate.mo.gov/07info/members/newsrel/d25/022207.pdf (last checked April
12,2008).
136id
1n See Stephen M. Scanlon, Should Missouri Farmers of Genetically Modified Crops be
Held Liablefor Genetic Drft and Cross-Pollination?, 10 Mo. ENVTL. L. & POL'Y REV.
1, 2 (2003) (citing Tichenor v. Vore, 953 S.W.2d 171, 176 (Mo. App. S.D. 1997)).
552
RIDING THE CERCLA-CYCLE
economic, and environmental issue that Missouri, and the United States,
will grapple with for years to come.
LEE STOCKHORST
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